US$ 23.05
ascendis pharma glp-1 receptor agonists weight management diabetes treatments Pharmacology Consult: for loss Novo inks Ascendis deal to
Description
2022 Dec;65(12):1925-1966

Sarcopenia in mid-life predicts worse outcomes from any future illness, surgery, or fall

Proper training for personnel handling and transporting these drugs further ensures compliance with cold chain protocols

She also had type 2 diabetes, so had been taking the GLP-1 inhibitor drug dulaglutide (Trulicity)

Japan Market Poised for Steady Growth Amid Aging Population and Rising Diabetes Burden The Japan GLP-1 receptor agonist market is expected to grow steadily during the forecast period, driven by a rising elderly population and a high prevalence of type 2 diabetes
